%0 Journal Article
%T Clinical Experience with Generic Rasagiline (Ralago<sup>®</sup>) in Patients with Parkinson¡¯s Disease: An Open-Label, Multicenter, Observational Study
%A D¨¢vid Pint¨¦r
%A J¨²lia Lajtos
%A J¨®zsef Janszky
%A Norbert Kov¨¢cs
%J Advances in Parkinson's Disease
%P 18-34
%@ 2169-9720
%D 2019
%I Scientific Research Publishing
%R 10.4236/apd.2019.82003
%X <p style=\"text-align:justify;\">
	<b><u><span style=\"font-family:Verdana;\">Background</span></u></b><span style=\"font-family:;\" \"=\"\"><span style=\"font-family:Verdana;\">: Antiparkinsonian pharmacotherapy represents one of the most important
ex</span><span style=\"font-family:Verdana;\">penses related to Parkinson¡¯s disease. The
application of generic drugs may help to reduce the economic burden of the
disease; however, efficacy and saf</span><span style=\"font-family:Verdana;\">ety
of these products have been less studied. </span><b><u><span style=\"font-family:Verdana;\">Objective:</span></u></b><span style=\"font-family:Verdana;\"> To
investigate the efficacy and safety of generic rasagiline (Ralago</span></span><sup><span style=\"font-family:Verdana;\"><sup>&reg;</sup></span></sup><span style=\"font-family:;\" \"=\"\"><span style=\"font-family:Verdana;\">) from a clinical perspective. </span><b><u><span style=\"font-family:Verdana;\">Methods</span></u></b><span style=\"font-family:Verdana;\">: The Clinical Global Impression of Severity scale was used to rate the
most important motor and non-motor symptoms at baseline and 12 weeks after the
initiation of Ralago</span></span><sup><span style=\"font-family:Verdana;\"><sup>&reg;</sup></span></sup><span style=\"font-family:Verdana;\">. Patients also identified
symptoms which were the m</span><span style=\"font-family:;\" \"=\"\"><span style=\"font-family:Verdana;\">ain sources of their
disability and distress in everyday life. </span><b><u><span style=\"font-family:Verdana;\">Results</span></u></b><span style=\"font-family:Verdana;\">: A total of 499
patients were enrolled (231 females, mean age: 73.2 ¡À 9.1 years, mean duration
of disease: 3.6 ¡À 3.7 years). Of them,
486 patients completed the study protocol. Both motor and non-motor symptoms
showed</span><span style=\"font-family:Verdana;\"> improvement during 12-week Ralago</span></span><sup><span style=\"font-family:Verdana;\"><sup>&reg;</sup></span></sup><span style=\"font-family:Verdana;\"> treatment. Adverse events were rare, and the
majority </span><span style=\"font-family:Verdana;\">of them were not considered
as serious. </span><b><u><span style=\"font-family:Verdana;\">Conclusions</span></u></b><span style=\"font-family:Verdana;\">: The generic rasagiline (Ralago</span><sup><span style=\"font-family:Verdana;\"><sup>&reg;</sup></span></sup><span style=\"font-family:Verdana;\">) is an effective and safe generic product.</span><span style=\"font-family:Verdana;\"></span> 
</p>
%K Parkinson¡¯s Disease
%K Rasagiline
%K Generic Antiparkinsonian Drugs
%K Health-Related Quality of Life
%U http://www.scirp.org/journal/PaperInformation.aspx?PaperID=92621